Shortage of Riluzole Oral Suspension
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Riluzole Oral Suspension, affecting one specific presentation while others remain available, as noted in their database.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Riluzole.
Shortage of Riluzole Oral Suspension
What's in Shortage
The generic drug Riluzole Oral Suspension, with brand names TEGLUTIK and TIGLUTIK, is in a current shortage status. It is an oral suspension in the neurology therapeutic category. The shortage was first posted on 01/26/2024 and last updated on 04/01/2026.
Which Manufacturers Are Affected
The manufacturer affected is EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.). Their availability status is as follows:
- Available for Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1), with contact info: 610-937-6172
- Available for Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1), with contact info: 610-937-6172
- Available for Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1), with contact info: 610-937-6172
- Unavailable for Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-2), with related info: Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing, and contact info: 610-937-6172
Why There's a Shortage
For the unavailable presentation, the shortage is due to product manufacturing interrupted due to testing. No specific reason was provided for the other presentations.
What Patients Should Do
Patients should talk to their pharmacist or healthcare provider about the availability of Riluzole Oral Suspension. They can also contact the manufacturer for more information. Patients should consult their healthcare provider for any advice and not make changes to their medication regimen without professional guidance.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,651 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.